. Author manuscript; available in PMC: 2019 Feb 27.

Published in final edited form as: J Allergy Clin Immunol. 2018 Jan 17;142(2):497–509.e9. doi: 10.1016/j.jaci.2017.09.052

Table I. Demographic, clinical, and serologic characterization of the SA population.

	BM32 low	BM32 high	Placebo	Total
No. of subjects	53	60	53	166
Age (V1)
Mean	28.7	29.8	29.1	29.2
Median	26	28	25	26
Range	18-53	18-52	18-58	18-58
Sex (V1)
Male (%)	34 (64.2)	36 (60.0)	31 (58.5)	101 (60.8)
Ethnic group (V1)
White (%)	53 (100.0)	59 (98.3)	52 (98.1)	164 (98.8)
Asian (%)	0 (0.0)	1 (1.7)	0 (0.0)	1 (0.6)
African (%)	0 (0.0)	0 (0.0)	1 (1.9)	1 (0.6)
Severity of grass pollen allergy (V1)
Moderate (%)	34 (64.1)	39 (65.0)	37 (69.8)	110 (66.3)
Severe (%)	19 (35.9)	21 (35.0)	16 (30.2)	56 (33.7)
Subjects with a history of grass pollen–associated asthma (V1)
No. (%)	20 (38.5)	12 (20.0)	14 (26.4)	46 (27.7)
Total IgE (kU/L) (V5)
Mean	273	179	194	214
Median	118	117	129	119
Range	20.6-1235	10.4-2217	8.8-1121	8.8-2217
sIgE, Timothy grass (kU_A/L [V1])
Mean	35.0	29.0	33.3	32.3
Median	21.0	21.6	19.9	21.0
Range	3.45-100	3.48-100	2.63-100	2.63-100
sIgE, Timothy grass (kU_A/L [V5])
Mean	29.9	21.9	26.0	25.8
Median	17.0	17.3	17.4	17.3
Range	2.07-100	2.95-76.3	2.20-100	2.07-100
sIgE, Phl p 1 (kU_A/L [V5])
Mean	17.5	12.4	15.9	15.2
Median	8.56	9.82	8.46	8.67
Range	1.13-95.4	0.10-41.8	0.66-81.4	0.10-95.4
sIgE Phl p 2 (kU_A/L [V5])
Mean	4.04	2.47	5.11	3.82
Median	1.92	1.67	2.27	1.76
Range	0.10-20.8	0.10-18.0	0.10-32.7	0.10-32.7
sIgE, Phl p 5 (kU_A/L [V5])
Mean	20.0	14.1	14.5	16.1
Median	11.0	9.12	6.12	9.34
Range	0.10-100	0.10-100	0.10-100	0.10-100
sIgE, Phl p 6 (kU_A/L [V5])
Mean	7.96	6.31	5.11	6.45
Median	3.71	2.66	2.05	2.99
Range	0.10-67.3	0.10-67.9	0.10-50.2	0.10-67.9
SPT, grass pollen (mm² [V5])
Mean	67.7	77.3	77.0	74.2
Median	51.3	76.2	68.0	65.2
Range	8.17-241	7.72-190	0.75-443	0.75-443

V1 and V5 denote visits 1 and 5 before treatment, respectively.